Morgan Stanley downgraded Waterdrop from Overweight to Equal-Weight and set a new price target of $2.00 from $5.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2025 | $2.00 | Buy → Neutral | Goldman |
| 9/16/2022 | $2.00 → $2.10 | Equal-Weight → Overweight | Morgan Stanley |
| 3/25/2022 | $5.00 → $2.00 | Overweight → Equal-Weight | Morgan Stanley |
Goldman downgraded Waterdrop from Buy to Neutral and set a new price target of $2.00
Morgan Stanley upgraded Waterdrop from Equal-Weight to Overweight and set a new price target of $2.10 from $2.00 previously
Morgan Stanley downgraded Waterdrop from Overweight to Equal-Weight and set a new price target of $2.00 from $5.00 previously
6-K - Waterdrop Inc. (0001823986) (Filer)
SCHEDULE 13G/A - Waterdrop Inc. (0001823986) (Subject)
6-K - Waterdrop Inc. (0001823986) (Filer)
3 - Waterdrop Inc. (0001823986) (Issuer)
3 - Waterdrop Inc. (0001823986) (Issuer)
3 - Waterdrop Inc. (0001823986) (Issuer)
BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2025 and a cash dividend. During the fourth quarter, Waterdrop reported net operating revenue of 1,411.2 million，representing a 105.5% year-over-year increase. Net profit attributable to ordinary shareholders reached RMB162.1 million, representing a solid year-over-year increase of 62.7%，sustaining profitability for the sixteenth consecutive quarter.For the year of 2025, Waterdrop reported net operating revenue increased by
BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2025 and a cash dividend. Financial and Operational Highlights for the Fourth Quarter of 2025Accelerated Profit Expansion: In the fourth quarter of 2025, operating profit was RMB83.9 million (US$12.0 million), marking a strong year-over-year increase of 58.4%. Net profit attributable to our ordinary shareholders reached RMB162.1 million (US$23.2 million), representing a solid year-over-y
BEIJING, March 11, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE:WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before U.S. markets open on Wednesday, March 25, 2026. Waterdrop's management team will hold a conference call on March 25, 2026 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:International:1-412-317-6061United States Toll Free:1-888-
BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2025 and a cash dividend. During the fourth quarter, Waterdrop reported net operating revenue of 1,411.2 million，representing a 105.5% year-over-year increase. Net profit attributable to ordinary shareholders reached RMB162.1 million, representing a solid year-over-year increase of 62.7%，sustaining profitability for the sixteenth consecutive quarter.For the year of 2025, Waterdrop reported net operating revenue increased by
BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2025 and a cash dividend. Financial and Operational Highlights for the Fourth Quarter of 2025Accelerated Profit Expansion: In the fourth quarter of 2025, operating profit was RMB83.9 million (US$12.0 million), marking a strong year-over-year increase of 58.4%. Net profit attributable to our ordinary shareholders reached RMB162.1 million (US$23.2 million), representing a solid year-over-y
BEIJING, March 11, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE:WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before U.S. markets open on Wednesday, March 25, 2026. Waterdrop's management team will hold a conference call on March 25, 2026 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:International:1-412-317-6061United States Toll Free:1-888-
BEIJING, March 12, 2025 /PRNewswire/ -- On March 12, 2025, Waterdrop Inc. (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the fourth quarter and Fiscal Year ended December 31, 2024. During the fourth quarter, Waterdrop reported net operating revenue of RMB 686.8 million. Net profit attributable to ordinary shareholders totaled RMB 99.6 million, up 68.5% from the same quarter of previous year, sustaining profitability for the twelfth consecutive quarter. Operating expenses, including sales and marketing expenses, general and administrative expenses, research and development ex
BEIJING, March 12, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Mr. Chen Lin as an independent director and a member of the audit committee of the Company's board of directors (the "Board"), replacing Mr. Ning Zhu, effective March 11, 2025. Mr. Ning Zhu has tendered his resignation as an independent director and a member of the audit committee of the Board due to personal reasons. The resignation of Mr. Zhu was not due to any dispute or disagreement with the Company. Mr. Chen Lin has served at various positions at Th
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion of a $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Eme
SC 13G/A - Waterdrop Inc. (0001823986) (Subject)
SC 13G/A - Waterdrop Inc. (0001823986) (Subject)
SC 13G/A - Waterdrop Inc. (0001823986) (Subject)